Reviewing BioCardia


BioCardia and Acorda Therapeutics are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Acorda Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 39.26%.



from Biotech News